The outcome of this study should be interesting. I

Quote:

---

The outcome of this study should be interesting. I’m glad there is a separate arm with Leronlimab alone.

The drug (Temozolimide) methylates DNA, inhibiting repair, leading to apoptosis and cell death

---

I'm glad there's a seperate leronlimab arm too. Leronlimab may be as effective as Temozolimide in it's particular action and offers so much more. Wouldn't Merck be surprised if the study results can isolate that effect.

CCR5 reduces methylation which leronlimab would reverse which is why it's been shown to enhance tumor cell death in our cancer trials.